dr. hodes. >> thank you, chairman collins and ranking member mccaskill and members of the committee. let me begin by thanking you for the opportunity to be here and for the support that you, congress, the administration, have provided to nih and the research and to everyone in or near this room for the opportunity to be a part of what we are doing. i would like to spend the next few minutes just giving some of the examples of the state of research in alzheimer's disease, the state which gives us great hope, hope greater than ever before the progress we are seeing now will lead to improvements and ultimately the ability to treat, cure and prevent alzheimer's disease. if we can move to the next slide this probably needs no elaboration. this is as referred to by chairman collins, but an illustration of where we stand now in terms of the number of people affected with alzheimer's disease, 5.1, 5.2 million and projection for its increase, two to three-fold in the next decade it is we don't change th

dr. hodes mentioned, is to effectively treat and prevent alzheimer's disease by 2025. this goal is but a short ten years away. an essential feature of the recommendation submitted to the secretary and to congress includes the recommendation that the federal government spend at least $2 billion a year in research on alzheimer's disease. as chairman collin was has indicated, this fig your -- pales in comparison to what we spend on cancer, hiv/aids and yard yo vascular disease, yet in those diseases, there have been significant progress made about regard to redog the number of deaths per year, yet the annual death rate for alzheimer's disease is escalating. again, alzheimer's disease is an incurable disorder with no survivors. in 2013, the united kingdom prime minister, david cameron, used the final event of the g-8 presidency to host a summit on dementia. in preparation for that meeting, professor nick fox of university college london and i wrote a commentary for the journal, "the lancet," shutti